19,694 Shares in Exelixis, Inc. $EXEL Purchased by FCG Investment Co

Key Points

• FCG Investment Co has acquired 19,694 shares of Exelixis, Inc. for approximately $868,000, marking a new position in the biotechnology firm.
• Exelixis reported an earnings per share (EPS) of $0.75 for the last quarter, exceeding analysts' estimates but with a 10.8% year-over-year revenue decline.
• The consensus rating for Exelixis shares is a "Moderate Buy" with an average price target of $44.42 according to multiple analysts.

FCG Investment Co acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 19,694 shares of the biotechnology company's stock, valued at approximately $868,000.

Several other large investors have also bought and sold shares of the company. Frank Rimerman Advisors LLC lifted its stake in shares of Exelixis by 4.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company's stock valued at $234,000 after purchasing an additional 285 shares during the period. Farther Finance Advisors LLC lifted its position in Exelixis by 6.1% during the first quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock valued at $195,000 after buying an additional 307 shares during the period. Rathbones Group PLC lifted its position in Exelixis by 5.3% during the first quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company's stock valued at $253,000 after buying an additional 347 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Exelixis by 9.2% during the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company's stock valued at $161,000 after buying an additional 367 shares in the last quarter. Finally, Byrne Asset Management LLC grew its position in shares of Exelixis by 129.0% in the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after buying an additional 400 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Down 0.6%

EXEL opened at $38.69 on Friday. The stock has a market capitalization of $10.42 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 0.80 and a beta of 0.32. The firm has a 50 day moving average price of $39.08 and a 200-day moving average price of $39.70. Exelixis, Inc. has a twelve month low of $25.17 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm's revenue was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a "buy" rating in a research report on Tuesday, June 24th. Barclays initiated coverage on Exelixis in a research report on Wednesday, September 17th. They issued an "equal weight" rating and a $40.00 price target on the stock. Bank of America raised their price objective on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research report on Thursday, June 5th. JMP Securities reissued a "market outperform" rating and issued a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Finally, Zacks Research downgraded Exelixis from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 26th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and an average price target of $44.42.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.